Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Short-term Investments: 2010-2024

Historic Short-term Investments for Myriad Genetics (MYGN) over the last 13 years, with Jun 2024 value amounting to $4.9 million.

  • Myriad Genetics' Short-term Investments fell 73.94% to $4.9 million in Q2 2024 from the same period last year, while for Jun 2024 it was $4.9 million, marking a year-over-year decrease of 73.94%. This contributed to the annual value of $8.8 million for FY2023, which is 84.83% down from last year.
  • Latest data reveals that Myriad Genetics reported Short-term Investments of $4.9 million as of Q2 2024, which was down 33.78% from $7.4 million recorded in Q1 2024.
  • Over the past 5 years, Myriad Genetics' Short-term Investments peaked at $103.2 million during Q1 2022, and registered a low of $4.9 million during Q2 2024.
  • Its 3-year average for Short-term Investments is $41.9 million, with a median of $21.9 million in 2023.
  • As far as peak fluctuations go, Myriad Genetics' Short-term Investments soared by 279.41% in 2022, and later crashed by 87.52% in 2023.
  • Quarterly analysis of 5 years shows Myriad Genetics' Short-term Investments stood at $33.7 million in 2020, then skyrocketed by 141.54% to $81.4 million in 2021, then fell by 28.75% to $58.0 million in 2022, then plummeted by 84.83% to $8.8 million in 2023, then slumped by 73.94% to $4.9 million in 2024.
  • Its last three reported values are $4.9 million in Q2 2024, $7.4 million for Q1 2024, and $8.8 million during Q4 2023.